ARTICLE | Clinical News
DCF 987: Phase II
August 11, 2003 7:00 AM UTC
BCY completed enrollment in a Canadian Phase II trial of DCF 987. The double-blind, placebo-controlled study is designed to assess the effect of both 500 and 1000 mg twice-daily doses of DCF 987 on pu...